VeonGen Therapeutics GmbH
2 clinical trials · 2 recruiting · INDUSTRY
Trials by VeonGen Therapeutics GmbH
RECRUITINGPhase 1 / Phase 2NCT07002398
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt...
This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for...
Sponsor: VeonGen Therapeutics GmbHEnrolling: 151 location
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
RECRUITINGPhase 1NCT06291935
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations...
The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis...
Sponsor: VeonGen Therapeutics GmbHEnrolling: 61 location
Retinitis Pigmentosa